Promising Targets in Anti-cancer Drug Development: Recent Updates

Author(s): Bhupinder Kumar, Sandeep Singh, Ira Skvortsova*, Vinod Kumar*

Journal Name: Current Medicinal Chemistry

Volume 24 , Issue 42 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Cancer is a multifactorial disease and its genesis and progression are extremely complex. The biggest problem in the anticancer drug development is acquiring of multidrug resistance and relapse. Classical chemotherapeutics directly target the DNA of the cell, while the contemporary anticancer drugs involve molecular-targeted therapy such as targeting the proteins possessing abnormal expression inside the cancer cells. Conventional strategies for the complete eradication of the cancer cells proved ineffective. Targeted chemotherapy was successful in certain malignancies however, the effectiveness has often been limited by drug resistance and side effects on normal tissues and cells. Since last few years, many promising drug targets have been identified for the effective treatment of cancer. The current review article describes some of these promising anticancer targets that include kinases, tubulin, cancer stem cells, monoclonal antibodies and vascular targeting agents. In addition, promising drug candidates under various phases of clinical trials are also described. Multi-acting drugs that simultaneously target different cancer cell signaling pathways may facilitate the process of effective anti-cancer drug development.

Keywords: Anticancer, tubulin inhibitor, kinases, cancer stem cells, multi-drug resistance, multi-targeting agents.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [4729 - 4752]
Pages: 24
DOI: 10.2174/0929867324666170331123648
Price: $65

Article Metrics

PDF: 189
HTML: 58